Clinical Trial Update: A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ramucirumab to placebo in hepatocellular carcinoma with elevated baseline AFP has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2019-05-17